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Abstract
Rare diseases collectively exert a global public health burden in the severity of their manifestations and the total
number of people they afflict. For many patients, considerable barriers exist in terms of access to appropriate care,
delayed diagnosis and limited or non-existing treatment options. Motivated by these challenges, the rare disease
patient community has played a critical role, elevating the patient voice and mobilizing legislation to support the
development of programs that address the needs of patients with rare diseases.
The US Orphan Drug Act of 1983 served as a key milestone in this journey, providing a roadmap for other countries
to introduce and implement similar orphan drug legislation; more recently, the European Union (EU) has gone
further to encourage the widespread adoption and implementation of rare disease plans or strategies designed to
more adequately address the comprehensive needs of patients with rare diseases. Despite these legislative efforts
and the growing contributions of patient advocacy groups in moving forward implementation and adoption of
rare disease programs, gaps still exist across the policy landscape for several countries. To gain deeper insights into
the challenges and opportunities to address key needs of rare disease patients, it is critical to define the current
status of rare disease legislation and policy across a geographically and economically diverse selection of countries.
We analyzed the rare disease policy landscape across 11 countries: Germany, France, the United Kingdom, Canada,
Bulgaria, Turkey, Argentina, Mexico, Brazil, China, and Taiwan. The status and implementation of policy was
evaluated for each country in the context of key patient needs across 5 dimensions: improving coordination of
care, diagnostic resources, access to treatments, patient awareness and support, and promoting innovative research.
Our findings highlight the continuing role of the patient community in driving the establishment and adoption of
legislation and programs to improve rare disease care. Further, we found that while national rare disease plans
provide important guidance for improving care, implementation of plans is uneven across countries. More research
is needed to demonstrate the effect of specific elements of rare disease plans on patient outcomes.
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Background
Rare disease is a global public health issue
Individual rare diseases by definition affect few people,
but cumulatively have a major impact on public health.
While the definition of rare disease varies by country,
prevalence-based definitions range from 1 in 500,000 to
1 in 2000 [1, 2]. In the United States, the Orphan Drug
Act of 1983 defined a rare disease by the number of af-
fected people; by this definition, the actual prevalence of
rare diseases varies with population numbers [3]. A dis-
ease is considered rare if it affects fewer than 200,000 in-
dividuals, whereas other countries define a rare disease
based on prevalence rates [1, 3–6]. For example, in Eur-
ope, diseases are considered rare when they affect fewer
than 5 individuals in 10,000 [7]. In Brazil, the definition
is similar to the World Health Organization definition,
as those affecting less than 65 out of 100,000 individuals
[8]. In Taiwan, a rare disease is defined as a disease that
is prevalent in fewer than 1 in 10,000 individuals [9].
An estimated 5000 to 8000 rare diseases have been
identified worldwide, affecting approximately 6 to 8% of
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the population [10]. While rare diseases exhibit consid-
erable diversity in etiology and clinical presentation,
most are severely disabling with serious effects on life
expectancy and physical and mental abilities [11]. Fur-
ther, rare diseases constitute a major economic burden
independent of a country’s size and demographics; these
costs arise from increased healthcare spending and lost
productivity [1, 12–14].
Many rare disease patients experience barriers in ac-
cess to care, and fewer than 10% receive disease-specific
treatment [15]. Delayed diagnoses, limited access to re-
sources, and absence of specific therapies often preclude
patients from receiving proper, timely care. Even brief
delays in diagnosis may have profound effects on out-
comes; for over 40% of rare disease patients, treatment
delays are precipitated by misdiagnoses [11, 16]. When
patients are diagnosed, many are unable to access re-
sources such as centers of expertise, coordinated care,
patient support systems, and effective treatment. For
many rare diseases, there are no effective treatments and
information on disease progression is limited. Therefore,
research into the natural history and underlying patho-
physiological mechanisms of rare diseases is necessary to
develop a foundation for discovering targeted medicines.
The patient community plays a critical role toward ad-
dressing these challenges, by elevating the patient voice
and partnering in the development of programs to ad-
dress the needs of patients with rare diseases. Approxi-
mately three and a half decades ago, the patient
movement to create awareness and support for rare dis-
eases took shape in the United States under the banner
of the National Organization for Rare Disorders. Joint
efforts under the leadership of a mother (Abby Myers), a
congressman (Henry Waxman), and an actor (Jack Klug-
man) garnered the national stage in a series of headline
events that captured the public imagination and mobi-
lized Congress to pass the world’s first orphan drug le-
gislation in 1983. This was a seminal event in the
development of national rare disease policy and trans-
formed the landscape for rare disease drug development;
from 10 new drugs in the decade preceding the Orphan
Drug Act to over 500 new drugs in the succeeding three
decades [3, 17]. The success of the Orphan Drug Act in-
formed efforts to introduce orphan drug legislation in
other countries [18] such as Japan, Singapore, South
Korea, Australia, and the European Union.
While these legislative efforts were more focused on
the development of innovative treatments for rare dis-
ease patients, the European Union went one step further,
broadly ensuring that comprehensive policy programs
addressed all needs of rare disease patients. In 2009, the
European Council adopted the “Recommendation on an
Action in the Feld of Rare Diseases,” which supports the
adoption of national plans and strategies for responding
to rare diseases. The council recommended the develop-
ment of national plans or strategies to address compre-
hensive needs, including diagnosis, treatment, care, and
support of citizens with rare diseases [10]. Countries
were encouraged to consider in these plans aspects such
as the improvement in the awareness of rare diseases,
the support for research into rare diseases, the develop-
ment of centers of expertise, the empowerment of pa-
tient organizations, and the implementation of a robust
healthcare infrastructure.
A number of countries preceded the European Recom-
mendation and France was already ahead of other mem-
ber states, adopting the First National Plan for Rare
Diseases in 2004 [19]. The plan created centers of ex-
pertise that were responsible for coordinating diagnosis
and provision of health and social care, writing national
protocols for diagnosis and care, collecting data, and
conducting clinical trials. France’s National Plan served
as the impetus and model for all European Union coun-
tries, which have developed or are in the process of de-
veloping National Plans or Strategies for rare diseases
[19]. In the Asia Pacific region, Taiwan had a set of
established programs, where rare diseases are included
in the National Disability Registry and government social
services programs for patients with rare diseases that in-
clude health-related subsidies and tax deductions, school
fee reductions, employment supports, and transportation
discounts. Similarly, Japan had enacted special legislation
in 1972 to address “nanbyo,” or rare and intractable dis-
eases, with about 130 “tokutei shikkan” or special desig-
nated rare diseases receiving public subsidized care [20].
As national plans for rare diseases evolve, patients and
patient advocates continue to play an integral role in
moving forward the implementation and adoption of the
programs outlined in the plan. The European Project for
Rare Diseases National Plans Development (EURO-
PLAN) was a project co-funded by the EU Commission
to promote and implement National Plans or Strategies
to tackle rare diseases, to share relevant experiences
within countries, linking national efforts with a common
strategy at a European level [21]. Importantly, EURO-
PLAN formally included organized patient input and has
played a key role within the European Union in guiding
the establishment and implementation of National Plans
or Strategies for rare diseases [21]. To this end, EURO-
PLAN included a specific role for the European
Organization for Rare Diseases a European umbrella
group of non-governmental associations of patients with
rare diseases. The European Organization for Rare Dis-
eases ensured that EUROPLAN processes were reflective
of patient viewpoints, in part by organizing a series of
conferences to discuss coordination of the European
Union and national policy [16]. A committee of rare dis-
ease experts, the European Union Committee of Experts
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on Rare Diseases (EUCERD) Joint Action, was set up by
the European Commission to formulate and implement
policy to combat rare diseases [22, 23]. The mandate of
EUCERD Joint Action ended in July 2013 and been re-
placed by the EC Expert Group on Rare Diseases in
2013 [24]. The EC Expert Group continues to have a
strong presence of patients’ organizations in the field of
rare diseases. The elaboration of policies in the field of
rare diseases and improvement of the codification of
rare diseases has been continued through the scope of
RD-Action, a Joint Action co-funded via the 3rd EU
Health Programme for the years 2015–2018. The Euro-
pean Organization for Rare Diseases (EURORDIS) con-
tinues to play an integral role representing the voice of
patients and driving forward the adoption of important
rare disease and orphan medicine legislations at the
European level. In addition, similar organizations at a
national level, such as the Canadian Organization for
Rare Disorders (CORD), actively play an instrumental
role in driving forward policy development. Both organi-
zations have developed key position statements that out-
line top priorities that public decision makers should
consider when addressing the needs of rare disease pa-
tients. While each countries policies and programs re-
flect the priorities of their health care system and needs
of rare disease patients, the EURODIS and CORD pos-
ition statements provide a general, but comprehensive
framework that could be applicable to a majority of
countries. As such, in this paper, we analyzed the rare
disease legislation and associated policies, regulations,
and programs across a diverse sample of 11 countries
according to the goals outlined in the European
Organization for Rare Diseases and Canadian
Organization for Rare Disorders position statements.
The objective of the review is to understand where there
are opportunities for further policy development by
examining how these policies and programs might align
with key needs of the rare disease community, which are
summarized in five dimensions: 1. improving coordin-
ation of care, 2. diagnostic resources, 3. access to treat-
ments, 4. patient awareness and support, and 5.
promoting innovative research. We also considered the
contributions of patient advocacy groups and included
some external measures of healthcare provision as an
initial consideration for how current rare disease policy
might align with the healthcare climate. The findings
from this study will inform future studies evaluating
how specific elements for National Plans or Strategies
for rare diseases translate to provision of care for rare
disease patients.
Methods
Information for this study was collected and analyzed
from 11 countries: Germany, France, the United
Kingdom (UK), Canada, Bulgaria, Turkey, Argentina,
Mexico, Brazil, China, and Taiwan. Countries included
in the analysis were selected to be geographically and so-
cioeconomically diverse, and represent a wide range of
rare disease policy development. The US was excluded
since it lacks a formal National Rare Disease Plan and
policy variation across states confounds comparisons
with other countries. The term National Rare Disease
Plan (NRDP) was used to refer to strategies and plans
that have been developed to support a comprehensive
and integrated approach to the delivery of health and so-
cial care for rare disease patients.
NRDPs were assessed using publically available official
documents and secondary research. Based on guidance
published [25] for rare disease policy, the following ele-
ments of NRDPs were evaluated for each country:
 National policy
 Access to treatment
 Diagnosis programs
 Coordination of care
 Research
 Patient engagement
The data were then assessed on the basis of our five
keys needs of the rare disease community: coordination
of care, diagnosis, access to treatments, patient aware-
ness and support, and research.
Results
The status of National Rare Disease Plan (NRDP) policy
elements for each of the 11 countries is presented in
Table 1. Countries were arranged in the table according
to overall healthcare/economic status, defined by gross
national income (GNI) per capita and healthcare spend-
ing (relative to gross domestic product [GDP]), and the
level of NRDP development. France and Germany have
well-developed NRDPs that are being implemented at
the national level. With the highest healthcare spending
and average wealth healthcare ranks of the 11 countries
surveyed, France and Germany have centralized national
funding, good access to treatments, robust research ini-
tiatives, coordinated networks, and cross-border collabo-
rations in place for rare diseases. The UK and Canada
have similar healthcare structures and NRDPs that are
both in the implementation stage with a number of ro-
bust programs in place. Bulgaria and Turkey have draft
or full plans approved and comparable levels of health-
care spending, but their plans have had limited imple-
mentation. Argentina, Mexico, and Brazil have similar
healthcare spending relative to gross domestic product
(GDP) but NRDPs are awaiting development or are very
early in implementation. Finally, the NRDPs of China
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and Taiwan are not proposed or are proposed but not
fully implemented.
The patient organization actions for each country are
presented within each of the five dimensions represent-
ing key needs of the rare disease community, summa-
rized below.
Dimension 1: Coordination of care
The term “coordination of care” was used to describe re-
sources designed to improve the provision of timely,
equitable, and evidence-informed care. Programs and
terminology vary by country but include Centers of Ex-
pertise (COEs) on rare diseases, integrated healthcare
administrative databases, and national registries for rare
diseases. While some countries attempt to coordinate
their approach to rare disease management using centers
of expertise, many countries do not, either because they
have not yet adopted this approach or are employing dif-
ferent strategies.
The concept of dedicated and comprehensive centers
for rare diseases was originally developed by France for
its first National Rare Disease Plan (NRDP), and then
adopted by the EU upon the request for national plans
nearly a decade ago. France has over 600 centers that
coordinate research, train healthcare professionals
(HCPs), and facilitate diagnoses (Table 1) [26]. Although
centers of expertise do not exist, per se, in the United
Kingdom (UK), the UK Strategy for Rare Diseases rec-
ommended the creation of specialist centers to deliver
coordinated and expert care required to support the
needs of rare disease patients [27]. The Birmingham
Centre for Rare Diseases is an example of the way one
hospital has created a specialist center for treating pa-
tients with rare diseases. In addition, the English Na-
tional Health Service lists about 150 providers of highly
specialized services, some of which are directed at rare
diseases, such as liver transplant services, enzyme re-
placement therapy, and proton beam therapy for specific
cancer treatments [28]. Further, the European Union re-
cently issued criteria for designating European Reference
Networks (ERNs) across the European Union for treat-
ing rare medical conditions and in December 2016 ap-
proved the first wave of 23 European Reference
Networks (ERN)s [27, 29].
In the Asian countries surveyed, no formal NRDPs for
Centers of Expertise are in place. The Taiwanese Bureau
of Health Promotion has approved medical institutions
to serve as centers for diagnosing and treating rare dis-
eases, and Taiwan has at least 10 approved genetic coun-
seling centers [30]. However, the coordinated care across
centers is not fully developed. Given the relatively small
geographic size of Taiwan, patients may not have to
travel far to access treatment, but, in larger countries,
dispersal of uncoordinated resources is a challenge. To
this point, barriers in the coordination of care in Latin
American countries are due to large population sizes
spread across vast landscapes, with many patients lo-
cated far from urban centers where centralized expertise
tends to be located. However, to support access to ex-
pertise in rural areas, many countries are employing
technology to address this issue. In Argentina, the
Health Ministry recently launched Cibersalud, an in-
novative tool to strengthen the network of specialists in
the country and facilitate referrals, diagnosis, and moni-
toring. Cibersalud seeks to promote consultations
among healthcare professionals from different establish-
ments in the country and to assist teaching activities,
through the provision of technological equipment and
the development of applications that allow videocon-
ferencing between establishments. More recently, the
Ministry of Health launched an interactive course on
Rare Diseases aimed at strengthening the diagnosis of
rare diseases. The course is intended for healthcare
professionals, including pediatrics, family medicine
and general practitioner residents of public hospitals
and training is conducted through on online discus-
sion on clinical cases and biweekly telemedicine meet-
ings (i.e. Cibersalud) [31, 32].
In countries without formal centers for rare diseases,
patient groups are playing an active role in supporting
coordinated care. For example, in Argentina, the Pituit-
ary Diseases Association implemented “Hiptour” to pro-
vide medical guidance to professionals for the diagnosis
of pituitary diseases in new patients. In Mexico, the
Lysosomal Storage Disease Patient network has helped
to create a model of comprehensive care starting with
diagnosis and including treatment and support that
has garnered high-level political attention and en-
dorsement. However, it is centrally located and also
limited in outreach resources. Overall, identifying and
creating Centers of Expertise or comparable programs
represent an important step toward consolidating
existing rare disease expertise.
Dimension 2: Diagnosis
An accurate and timely diagnosis is predicated on avail-
ability of universal or highly accessible screening and
diagnostic programs and services. Across the surveyed
countries, policies and practices varied significantly.
Neonatal screening has the potential to contribute to an
early diagnosis and management of a fraction of rare dis-
eases when there is an effective intervention which can
avoid or mitigate severe consequences and/or death if
provided early enough Multiple conditions can be identi-
fied from a single bloodspot collected at birth. However
it is important to note that the composition of a new-
born screening panel can vary between regions, depend-
ing on local prevalence. A number of newborn screening
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programs commonly utilize criteria established by JMG
Wilson and F. Jungner in 1968 to decide whether a par-
ticular condition is a suitable candidate for screening [33].
A recent report on the practices of newborn screening im-
plemented in EU member states noted that most jurisdic-
tions also take guidelines of scientific societies in
consideration [34]. However, many aspects are subjective
and there is not always agreement about which disorders
should be part of the panel. With the advent of new diag-
nostic technologies, debates have currently arisen as to
how screening programs should adapt.
Many countries have implemented core programs of
neonatal screening (eg, Taiwan, Brazil, UK, Germany).
Taiwan has implemented a nation-wide newborn screen-
ing program that covers at least 26 diseases [30]. Simi-
larly, Germany tests for 14 conditions nationwide [35].
While this number is far removed from the total number
of identified rare diseases, only a limited number of neo-
natal screening assays are currently available. In 2016,
Canada announced that the Health Ministers had agreed
to a list of 22 core conditions for newborn screening
programs across all provincial and territorial jurisdic-
tions, although some provinces were already routinely
testing for 30+ diseases [36]. These requisites are all
considerably lower than the number of rare diseases that
could be tested with a single bloodspot, and this is true
of most countries globally (except for the United States,
where some states test for 50 or more diseases). In most
of the countries surveyed, there was a distinct lack of
formal programs for newborn screening and/or infra-
structure/resources to support implementation, and this
was apparent across geographic regions, with Argentina,
Brazil, China, and Taiwan as leading examples where
other rare disease initiatives are in place or in planning
but limited attention has been given to core newborn
screening as an essential component of the rare disease
program. For example, in Brazil despite the progressive
translation of genetic research into a clinical field and ef-
forts by the Ministry of Health to establish the National
Newborn Screening Program (Programa Nacional de
Triagem Neonatal – PNTN) in 2001, progress still re-
mains to take place. Currently, only six diseases are in-
cluded in the formal newborn screening program [8, 37].
The panel still is modest when compared with the
screening programs of other countries, including Taiwan
with 26 diseases and Germany with 15 diseases.
Beyond the neonatal stage, diagnosis of rare diseases
can be even more difficult, resulting in long delays in
diagnosis and many misdiagnoses. Geographical chal-
lenges exacerbate this problem since long journeys to
visit specialists in different regions can impair accurate
diagnosis. In Mexico, some patients describe “medical
pilgrimages” to different doctors so as to reach a diagno-
sis, which can take 5 years or longer to achieve. A 2012
European Organization for Rare Diseases survey of eight
rare diseases representing 12,000 patients found that 25%
of patients had to wait between 5 and 30 years for a diag-
nosis, 40% received an initial erroneous diagnosis (leading
to wrong medical interventions), and 25% had to travel to
a different region to obtain a diagnosis [38]. Similarly, a
survey conducted by the Canadian Organization for Rare
Disorders found that about 20% of patients waited be-
tween 6 and 14 years to get a diagnosis and 60% consulted
3 to 20+ specialists on the way to a diagnosis. Importantly,
the availability of robust diagnosis and neonatal screening
programs can significantly reduce the patient diagnostic
odyssey and bridge the gap between disease onset and
diagnosis that, for many countries, represents a major bar-
rier in access to care.
Beyond awareness, an important strategy that is being
promoted in many countries is education for health care
practitioners to develop and expand expertise in rare dis-
eases. For example, the Argentinian Health Ministry
launched a tool to promote collaboration between profes-
sionals from different institutions across the country with
the goal of improving diagnosis. In many emerging health-
care systems, patient groups have taken an active role in
promoting professional education and collaboration. The
mobilization of a cystic fibrosis patient group was import-
ant in shaping decisions on what diseases are screened in
Brazil, while, in Mexico, patient groups have spurred the
development of early diagnosis funding, patient registries,
and efforts to raising rare disease awareness. Progress in
these directions has also occurred in the Asia-Pacific re-
gion, as the Taiwan Foundation for Rare Disorders (TFRD)
coordinates efforts with the Bureau of Health Promotion
to send specimens for testing in both foreign and domes-
tic labs for improving diagnosis and subsidizing costs for
rare disease testing at local hospitals.
Dimension 3: Access to treatments
The availability of rare disease treatments is addressed in a
number of national regulatory and legislative policies de-
signed to facilitate orphan drug designation, authorization,
and early access programs. The European Union passed
regulation (EC) No 141/2000, on orphan medicinal prod-
ucts in 2000, which covers all of the countries in the EU, in-
cluding the UK, Germany, Bulgaria and France represented
in this survey [39]. Further, the Committee for Orphan Me-
dicinal Products (COMP) was established with the respon-
sibility to recommend orphan designation of medicines for
rare diseases to the European Commission for final decision
[40]. In the European Union under the Regulation on Or-
phan Medicinal Products, medicines designated as orphan
medicinal products are provided incentives, including
protocol assistance. More recently, under the new Priority
Medicines (PRIME) scheme, the European Medicines
Agency (EMA) will offer early and enhanced scientific and
Dharssi et al. Orphanet Journal of Rare Diseases  (2017) 12:63 Page 7 of 13
regulatory support and enable accelerated assessment for
therapies that address significant unmet medical need and
offer the potential to bring a major therapeutic advantage
to patients [41]. Several other countries have expedited re-
view processes for orphan medicines, namely, Turkey,
Mexico, Brazil, China [42], Taiwan, and Canada [43], but
the criteria and process vary across the countries [44, 45].
In Brazil, the Agência Nacional de Vigilância Sanitária
(ANVISA), enacted a regulation (Resolution RDC 28) in
2007 that was further clarified in 2008 (RDC 16), stating
that orphan drugs should receive priority review and a deci-
sion on approval within 75 days [8]. In practice, the ap-
proval can take much longer and regulatory developments
are underway to improve review timelines. In Mexico,
despite no specific regulation for expedited approval, or-
phan medicinal products that have been approved by
other Agencies, such as the US Food and Drug Adminis-
tration or the European Medicines Agency, can be expe-
dited via a letter of recognition, and this mechanism has
shortened the authorization timeline to approximately
6 months [45]. Argentina has had similar success with a
program administered by the Argentinian National Ad-
ministration of Medicines, Food, and Medical Technology
that streamlines authorization requirements for orphan
drugs approved in the United States or the EU [45]. In
Canada, drugs for unmet needs or urgent situations are
eligible for expedited review.
For approved drugs, several countries have policies in
place to ensure timely patient access to treatment fol-
lowing regulatory approval. The UK’s National Institutes
for Health and Clinical Excellence (NICE) have estab-
lished a separate review process for “Highly Specialised
Therapies” which address ultra-orphan diseases (popula-
tion of less than 1 in 10,000) [46]. Elsewhere, within the
UK, The Scottish Medicines Consortium has also devel-
oped a new approach for reviewing rare disease medi-
cines designed to increase the influence of patients and
clinicians in the appraisal process. This “Patient and
Clinician Engagement group” can be convened to ad-
dress additional benefits that may not be represented in
the conventional clinical and economic assessment
process. Scotland also has a New Medicine Fund that
was recently expanded to £80 million a year allocated to
orphan drugs to ensure patient access to the most ad-
vanced therapies for diseases with unmet needs [47].
Similarly, in Bulgaria, special considerations are made
for health technology assessments for rare disease treat-
ments [48]. Further, Argentina employs a unique system
of refund that administers financial support to the Social
Health Service for certain drugs.
Dimension 4: Patient awareness and support
To what degree do patients and families get the educa-
tion and support for their rare disease? For each country,
we looked at three key indicators: public awareness di-
rected toward better identification and support, patient
education toward, among other things, engagement, ad-
vocacy and access to resources, and healthcare profes-
sional development to enhance diagnosis, treatment, and
care. The countries within our sample varied consider-
ably regarding who was involved, what was done, and
how much was achieved. Public awareness ranged from
comprehensive campaigns organized by dedicated na-
tional or international organizations to local awareness
initiatives implemented by stand-alone groups. In all
types of activities at all levels, patient organizations were
actively engaged. In the United Kingdom, France, and
Germany, established patient advocacy organizations,
both disease-specific and cross-disease, organized and
delivered a range of programs including education and
awareness conferences, patient guides to rare disease re-
search [49], and advocacy that spanned from support for
legislative acts to receptions with government leaders
[50]. In other countries where few other stakeholders
were active, strong national rare disease patient net-
works had the strongest influence on awareness, policy,
and health system response. Examples come from dis-
parate regions in our sample. For instance, in Bulgaria,
patient organizations implemented award-winning pro-
grams and support for rare diseases and, as importantly,
educated and motivated the rare disease patient commu-
nity not only to better access and navigate the healthcare
system but also to advocate for their cause, including a
call for legislative action to support their needs and play-
ing an integral role in the launch of 13 epidemiological
registries for rare diseases [51]. Similarly, national rare
disease collaborations in Argentina and Canada [52]
have prompted governments to implement legislation
and rare disease programs.
In the Asia-Pacific region where our sample consists
of China and Taiwan, rare disease patient support and
advocacy groups have been active but the scope and im-
pact of their involvement have varied, reflecting differ-
ences in political, economic, geographic, and healthcare
contexts. In Taiwan, the non-governmental organization
Taiwan Foundation for Rare Disorders (TFRD) deliber-
ately focused on obtaining government support for pa-
tients and families with rare diseases. To that end,
Taiwan Foundation for Rare Disorders has had a key role
in shaping rare disease policy and advocating for rare
disease patients. Established nearly two decades ago, the
organization leads education, awareness, and advocacy
efforts. Through coordinated efforts with governmental
organizations, Taiwan Foundation for Rare Disorders
helped pass the Rare Disease Control and Orphan Drug
Act of 2000. In China, where patient advocacy groups
are limited in number, localized and disease-specific,
medical rare disease groups have focused their efforts
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primarily on implementing educational initiatives. Re-
cent efforts have been made to bring together different
members of the stakeholder community. In 2011, Chin-
ese medical professionals issued a call to support health-
care, research, drug development, and epidemiological
studies for rare diseases [53]. Patient groups, charitable
organizations, and pharmaceutical companies have co-
hosted patient assistance programs and academic meet-
ings on International Rare Disease Day (February 29)
and China Birth Defects Prevention Day (September 12)
each year to raise public awareness and promote legisla-
tion for rare diseases. More recently, the Chinese
Organization for Rare Disorders, formed from an amal-
gamation of several groups and now representing ap-
proximately 40 rare diseases, has conducted several
highly innovative and impactful awareness and education
programs.
The Chinese and Taiwanese national networks are dis-
tinct in their focus and advocacy. Taiwan has more gen-
erally focused on within-country awareness raising and
lobbying, eschewing most international activities, while
the Chinese Organization for Rare Disorders has partici-
pated extensively in international arenas and also invited
many foreign patient advocates and other experts to
support their efforts in China. The differences are due to
context. Taiwan is geographically and population-wise a
small country, with a relatively strong economy and a
high-quality and well-resourced healthcare system that is
reasonably accessible to most patients. China, by con-
trast, is huge in both land mass and population with an
emerging economy and evolving healthcare system. The
Chinese Organization for Rare Disorders has sought to
attract international attention, best practices, and advo-
cacy support. To that end, the Chinese Organization for
Rare Disorders is a founding member of the Asia-Pacific
Alliance of Rare Disease Organizations and in 2014 was
host to the founding meeting of Rare Disease Inter-
national (RDI), a global alliance of rare disease patients
and advocates, to raise awareness, exchange information,
and increase the support of the rare disease cause. Par-
ticipation in the Rare Disease International meeting
breaks new ground in that it is an international, patient-
led advocacy group and the Chinese Organization for
Rare Disorders has the opportunity to host the Inter-
national Conference on Rare Diseases along with the
Rare Disease International meeting in 2017.
Some countries had plans that specifically included
health care professional education and training as a key
area of focus (Argentina, Germany), while other coun-
tries did not emphasize health care professional develop-
ment (Mexico, China), and this difference reflects, to
some degree, the differential involvement of HCPs in the
respective patient organizations. The Treatment and Re-
search Centre for Rare Diseases in Germany provides
continuing medical education through the German
Academy for Further Medical Training on Rare Diseases
program, which facilitates interactions and communica-
tions between physicians and relevant experts as well as
patient organizations [54]. In Brazil, a new National Pol-
icy of Integral Attention to People with Rare Diseases in-
cludes health care professional training to create
specialized teams of professionals to treat patients with
rare diseases.
Dimension 5: Research
Research for rare diseases is commensurate with overall
GDP as well as investment in innovation, science, and
healthcare; it has been relatively well funded with gov-
ernment investment in some countries (France,
Germany, UK, Canada) and not officially supported in
other countries (Turkey, Mexico). At a regional level,
the European Union has demonstrated a strong commit-
ment to rare disease research through the EU Frame-
work Programme for Research and Innovation. Under
the Seventh Framework Programmes for research
(2007–2013), over €620 million in support was granted
to over 120 collaborative research projects on rare dis-
eases. The funding facilitated the formation of multidis-
ciplinary teams from universities, research organizations,
industry, and patient organizations from across Europe
and beyond [55]. More recently, Horizon 2020, which
runs from 2014 to 2020 continues the European Union’s
strong commitment to funding rare disease research
[56]. At a country specific level, France, which currently
funds over 300 clinical research projects with collabora-
tions across national and international institutions, is
seen as a leader in the research space [26]. In Germany,
the Federal Ministry of Education and Research (BMBF)
is currently funding 12 research consortia since 2012,
with more than €23 million for three years and has sup-
ported additional funding through initiatives such as the
National Genome Research Network [54, 57]. In China,
the China Alliance for Rare Disease Prevention and
Treatment (CARDPT) has established the first ever na-
tional research program of prevention and treatment for
rare diseases, which intends to compile basic data on
rare disease pathophysiology and natural history, develop
and apply medical guidelines, and promote molecular
testing for rare diseases [58]. In Canada, the government
has committed funding through the Canadian Institutes
for Health Research for emerging teams and consortia of
researchers, as well as funding to maintain rare disease
models and funding for translational research (gene
identification, disease registries, and pilot clinics).
In several countries (Bulgaria, Turkey, Argentina,
Mexico, Brazil), there appear to be few or no national
initiatives to promote research and/or innovation in the
treatment of rare diseases. Research projects in
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Argentina are often conducted and funded through pri-
vate initiatives, research grants, or support from patient
organizations. Similarly, there is no long-standing initia-
tive to promote research on rare diseases at the national
level in Brazil; however, a bill intending to secure fund-
ing for rare and neglected disease-related research is
currently being reviewed by Congress.
Registries are important means of collecting disease,
demographic, and treatment data. France is a model for
national coordination of registries with their Banque
Nationale de Données Maladies Rares, a national
organization collecting and organizing data from centers
of expertise [59]. French patients enter the registry via the
center at which they receive care. In contrast, the UK,
Bulgaria, and Argentina, have national patient registries in
various stages of planning, but not implemented as of yet.
To help support the standardization and sharing of infor-
mation across rare disease registries, the European Com-
mission, within the EU Program of Community Action in
the field of Public Health, has initiated the establishment
of a European Platform for Rare Disease Registries to ad-
dress the challenge of standardizing and sharing informa-
tion across rare disease registries. [60]. This platform is
still in development. Orphanet tracks rare disease regis-
tries, databases, and biobanks so as to provide access to
this information to all stakeholders
Overall, a movement toward international registries is
evolving; for example, national rare disease registries are
not well developed in Turkey, but the country has partici-
pated in European registries such as TREAT-NMD (for
neuromuscular disease) and EUROCARE CF for cystic fi-
brosis. In Bulgaria, patient groups are working to modify
legislation addressing patient registries. In Brazil, no na-
tional registries exist for rare diseases, but patient associa-
tions have been able to collect information in disease-
specific areas. Some countries such as Mexico and China
have registries that are geographically dispersed and lo-
cally based, but lack standard structures to facilitate
patient-specific or whole-population analyses. While a na-
tional disability registry exists in Taiwan, registries specific
to rare disease are lacking; however, the Taiwan Society of
Thrombosis and Hemostasis is currently implementing a
patient registry specific to hemophilia.
Discussion
This study assesses the status of rare diseases in a sam-
ple of countries varying across economic, political,
healthcare factors and, at the same time, examines the
role of patient organizations in shaping national policy
and programs, including rare disease legislation, national
rare disease plans, and coordinated comprehensive ser-
vices directed to rare diseases. Most of the countries
represented in our sample (France, Germany, the UK,
Canada, Bulgaria, Argentina, Brazil, Mexico, and
Taiwan) have developed or announced intentions to de-
velop a National Rare Disease Plan, some of which are
officially recognized by the government but none, except
for France, are experiencing coordinated strategies and
policies toward comprehensive implementation. Indeed,
the scope and capacity vary considerably. In general,
countries that had higher healthcare spending and GNI
per capita, as well as national healthcare delivery systems
(France and Germany), also had well-developed national
plans that encompass early access to treatments, funding
for orphan drug access, diagnosis programs, coordinated
care, and strong research initiatives. In contrast, the UK
and Canada are similar in their financial metrics as well
as regionalized healthcare delivery structures, which
have challenged the development of national centers of
expertise, national guidelines for screening and diagno-
sis, and national criteria for access to therapy. Scotland,
Northern Ireland, and the United Kingdom have unique
drug assessment agencies. In the United Kingdom, the
National Institute for Healthcare Excellence (NICE) has
developed a separate body to assess “highly specialized
drugs” primarily for ultra-orphan indications [61], while
Scotland introduced a dedicated Rare Conditions Medi-
cines Fund [62] and Northern Ireland considers some
form of “ring fenced fund” for orphan drugs [63].
Turkey, Mexico, and China do not have orphan drug
legislation; analysis of external financial metrics revealed
that these countries also had the lowest GNI per capita
and healthcare spending. Countries that were lesser de-
veloped and/or had low healthcare spending and GNI
per capita were more likely to have National Rare Dis-
ease Plans (NRDP) that were not endorsed or imple-
mented. Still, some countries lacking formal NRDPs had
legislation/policies/regulations in place to improve ac-
cess to orphan drug treatment (eg, orphan drug classifi-
cation and accelerated review policies exist in Mexico).
Clearly, gaps exist between policy and practice. While a
number of countries have regulations specific to orphan
drugs that are designed to accelerate the authorization
process, streamlined processes do not necessarily expedite
or guarantee drug approval. In Brazil, the established time
frame for responding to authorization requests is 75 days,
but authorization times have varied from 13 to 30 months.
Bulgaria and Scotland were the only countries across
those surveyed to have specific funding allocated to or-
phan drugs. However, orphan drug licensing in Bulgaria is
often delayed from 1 to 6 years.
Despite the lack of formal NRDPs in place, several
countries have been able to make great progress in im-
proving processes in the rare disease landscape. Though
Canada did not have a national plan in place until Sep-
tember 2015, it has a very strong newborn screening
policy and well-established diagnostic centers that ex-
ceed what is available in many other countries [36]. In
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the Asia-Pacific region, Taiwan provides a model for good
programs that exist in the absence of specific policy; im-
proved screening and diagnosis programs are in develop-
ment, led by advocacy groups and funded by the
Taiwanese government. Further, Turkey has defined path-
ways for early treatment, designated specialized centers
for coordinated care, and provides screening and diagnosis
programs despite delayed implementation of its NRDP.
Several countries, inspired by the progress in Europe,
have adapted the consultation process and the core indi-
cators developed by the EUROPLAN project to support
the development and implementation of rare disease
plans and strategies [64]. In Canada, the Canadian
Organization for Rare Disorders played an instrumental
role in the strategic development and implementation of
the Canadian NRDP, which was distilled from 30+ other
NRDPs and asserts goals that are closely aligned with
those of the UK Strategy for Rare Diseases [65, 66]. Con-
sistent with the position of the European Organization
for Rare Diseases (EURODIS) on rare disease research
infrastructure, development, and governance, the inclu-
sion of patients as full and equal partners is a central
recommendation set forth by the Canadian Organization
for Rare Disorders (CORD) [65, 67].
In other countries, including Mexico, the patient advo-
cacy community is playing a large role in shaping discus-
sions, educating policy makers and driving the political
agenda to support national rare disease strategies by ac-
tively participating in small working groups with their
national Health Commissions. In several countries with-
out formal NRDPs, coordinated and influential disease-
specific advocacy groups have provided leadership in ad-
dressing gaps and implementing programs to support
key needs within the community. One such example of
the active role patient groups are playing in supporting
coordinated care in the absence of formal centers of ex-
pertise is seen in Argentina, where advocates from the
Pituitary Diseases Association in Argentina travel
around the country and provide medical updates on pi-
tuitary diseases to professionals to help identify and
diagnose patients. Similarly, patient groups in Bulgaria
have been working to modify legislation addressing pa-
tient registries to create a centralized registry that is
more compatible with international databases. In China,
the China Alliance for Rare Disease Prevention and
Treatment has established the first ever national re-
search program of prevention and treatment for rare dis-
eases. This demonstrates that despite national
prioritization, patient advocacy organizations can drive
successful implementation of programs that can help
support the key needs of rare disease patients. However,
despite the successful adoption of these programs, inte-
grated and coordinated strategies are necessary to ensure
holistic access to care and treatment for patients.
To further garner support, patients can further policy
development by creating alliances between/among orga-
nizations. The Iberoamérican Alliance for Rare Diseases
(ALIBER) has established a system across Ibero-
American countries to collaborate and share ideas sur-
rounding rare diseases. The recently formed Asia-Pacific
Alliance of Rare Disease Organizations (APARDO) rep-
resents a collaborative unification of national rare dis-
ease groups aimed at improving access to care and
treatment of rare diseases in China, Japan, India,
Australia, and Singapore. Importantly, many countries
analyzed in this study are members of Rare Disease
International (RDI), which provides a clear framework
for establishing and improving advocacy, awareness, in-
formation sharing and networking, research, and part-
nerships. As the landscape of rare disease policy
continues to evolve, the unification of rare disease pa-
tient organizations will be essential to driving innovative
research with shared resources and best practices, and
amplifying the role of the patient voice in the develop-
ment of programs to address the needs of the rare dis-
ease community.
Conclusion
According to the goals outlined in the EURORDIS and
CORD position papers, our study explored the rare dis-
ease legislation, associated policies, regulations, and pro-
grams across a diverse sample of countries through the
perspective of the key needs of the rare disease commu-
nity. Consistent with previous reports [25, 68, 69], our
analysis revealed substantial differences in rare disease
infrastructure across countries; however, it was limited
in the scope of the countries considered and was not de-
signed to assess the effect of specific policies and struc-
tures on patient outcomes. Subsequent analyses should
be conducted to correlate policy with the presence of ac-
tual programs and, ultimately, their effects on patient
care. Importantly, this information will provide a stra-
tegic framework that can structure ongoing dialogues
within and between countries so as to define best prac-
tices in rare disease management and harmonize efforts
across the globe in improving patient care.
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